tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Traws Pharma Reports 2024 Financial Results and CEO Change

Story Highlights
Traws Pharma Reports 2024 Financial Results and CEO Change

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Traws Pharma ( (TRAW) ) just unveiled an update.

On March 31, 2025, Traws Pharma announced its financial results for the year ending December 31, 2024, and highlighted significant progress in its investigational programs. The company reported positive data for its lead product candidate, tivoxavir marboxil, in treating bird flu, and ongoing FDA interactions for potential accelerated approval. Additionally, Traws Pharma completed a successful financing round, securing $20 million to support operations into Q1 2026. The company also announced the retirement of its CEO, Werner Cautreels, with Iain D. Dukes stepping in as Interim CEO.

More about Traws Pharma

Traws Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies to address critical threats to human health from respiratory viral diseases. The company’s primary products include tivoxavir marboxil, in development for bird flu, and ratutrelvir, in development for COVID-19.

YTD Price Performance: -72.32%

Average Trading Volume: 105,757

Technical Sentiment Signal: Buy

Current Market Cap: $12.08M

For an in-depth examination of TRAW stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1